Accepted Manuscript

Title: Agonistic antibodies in systemic sclerosis

Authors: Gianluca Moroncini, Silvia Svegliati Baroni,

Armando Gabrielli


PII: S0165-2478(17)30364-4

DOI: https://doi.org/10.1016/j.imlet.2017.10.007

Reference: IMLET 6126

To appear in: Immunology Letters

Received date: 31-7-2017 Revised date: 5-10-2017 Accepted date: 11-10-2017



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Agonistic antibodies in systemic sclerosis

Gianluca Moroncini, Silvia Svegliati Baroni, Armando Gabrielli

Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, 60126 Italy.

Correspondence: Armando Gabrielli, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, 60126 Italy. E-mail: a.gabrielli@univpm.it

Highlights

- Agonistic antibodies activate pathways leading to tissue and vascular damage in SSc
- Anti-endothelial cells antibodies (AECA) can induce either apoptosis or activation
- Antibodies targeting specific PDGFRα epitopes can induce skin fibrosis in vivo
- Anti-AT1R/ETaR antibodies are associated with severe SSc vascular manifestations
- Anti-muscarinic-3 receptor (M3R) antibodies may cause gastrointestinal dysfunction

Introduction

Systemic sclerosis (SSc) is characterized by microangiopathy, excessive fibrosis, and the presence of circulating autoantibodies to several cellular and extracellular components. The role of autoimmunity in generating the clinical and pathologic phenotypes in SSc has been long debated and is still matter of controversy. Distinct specificities of antinuclear antibodies (ANAs) are selectively detected in SSc patients and are associated with unique disease manifestations, but do not have a proven pathogenic role. A new group of autoantibodies reactive with cell surface receptors have been identified in SSc patients. They have been shown to directly activate pathways that may contribute to tissue and vascular damage. As such, they are proposed to have

Download English Version:

https://daneshyari.com/en/article/8738365

Download Persian Version:

https://daneshyari.com/article/8738365

<u>Daneshyari.com</u>